The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study

References

• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Zucca E, Arcaini L, Buske C et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17–29. doi:10.1016/j.annonc.2019.10.010
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298–308. doi:10.1016/j.annonc.2020.11.008
   PubMed Web of Science ®Google Scholar
• McKay P, Leach M, Jackson B, et al. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46–62. doi:10.1111/bjh.15283
   PubMed Web of Science ®Google Scholar
• Jain AG, Chang CC, Ahmad S, et al. Leukemic non-nodal mantle cell lymphoma: diagnosis and treatment. Curr Treat Options Oncol. 2019;20(12):85. doi:10.1007/s11864-019-0684-8
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–991. doi:10.1200/JCO.18.00605
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi:10.1016/S0140-6736(12)61763-2
   PubMed Web of Science ®Google Scholar
• Alderuccio JP, Arcaini L, Watkins MP, et al. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022;6(7):2035–2044. doi:10.1182/bloodadvances.2021006844
   PubMed Web of Science ®Google Scholar
• Cencini E, Fabbri A, Schiattone L, et al. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma. Leuk Lymphoma. 2019;60(3):833–835. doi:10.1080/10428194.2018.1504938
   PubMed Web of Science ®Google Scholar
• Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130(15):1772–1774. doi:10.1182/blood-2017-07-795302
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562. doi:10.1200/JCO.2008.21.3991
   PubMed Web of Science ®Google Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32(13):1338–1346. doi:10.1200/JCO.2013.52.2466
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409–1417. doi:10.1182/blood-2017-03-771915
   PubMed Web of Science ®Google Scholar
• Li YR, Wilson M, Yang L. Target tumor microenvironment by innate T cells. Front Immunol. 2022;13:999549. doi:10.3389/fimmu.2022.999549
   PubMed Web of Science ®Google Scholar
• Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci. 2022;29(1):83. doi:10.1186/s12929-022-00866-3
   PubMed Web of Science ®Google Scholar
• Cencini E, Fabbri A, Sicuranza A, et al. The role of tumor-associated macrophages in hematologic malignancies. Cancers. 2021;13(14):3597. doi:10.3390/cancers13143597
   PubMed Web of Science ®Google Scholar
• Cencini E, Fabbri A, Rigacci L, et al. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. Hematol Oncol. 2017;35(1):69–78. doi:10.1002/hon.2249
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Zheng T, Foss F, et al. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv. 2012;6(1):102–114. doi:10.1007/s11764-010-0164-4
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007;109(12):5439–5446. doi:10.1182/blood-2006-11-058040
   PubMed Web of Science ®Google Scholar
• Kube D, Hua TD, von Bonin F, et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin’s lymphoma: an exploratory study. Clin Cancer Res. 2008;14(12):3777–3784. doi:10.1158/1078-0432.CCR-07-5182
   PubMed Web of Science ®Google Scholar
• Gibson TM, Wang SS, Cerhan JR, et al. Inherited genetic variation and overall survival following follicular lymphoma. Am J Hematol. 2012;87(7):724–726. doi:10.1002/ajh.23184
   PubMed Web of Science ®Google Scholar
• Assis-Mendonça GR, Fattori A, Rocha RM, et al. An integrative microenvironment approach for follicular lymphoma: roles of inflammatory cell subsets and immune-response polymorphisms on disease clinical course. Oncotarget. 2020;11(33):3153–3173. doi:10.18632/oncotarget.27698
   PubMedGoogle Scholar
• Assis-Mendonça GR, Fattori A, Rocha RM, et al. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma. BMC Cancer. 2021;21(1):209. doi:10.1186/s12885-021-07891-9
   PubMed Web of Science ®Google Scholar
• Jin D, Jiang Y, Chang L, et al. New therapeutic ­strategies based on biasing IL-2 mutants for cancers and autoimmune diseases. Int Immunopharmacol. 2022;110:108935. doi:10.1016/j.intimp.2022.108935
   PubMed Web of Science ®Google Scholar
• Mousa SM, Makhlouf MM, Mohammed ET, et al. The influence of interleukin-2 gene polymorphisms on the risk and clinical outcome of non-Hodgkin lymphoma. Indian J Hematol Blood Transfus. 2021;37(4):549–554. doi:10.1007/s12288-020-01388-4
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. doi:10.1080/2162402X.2016.1163462
   PubMed Web of Science ®Google Scholar
• Ko B, Takebe N, Andrews O, et al. Rethinking oncologic treatment strategies with interleukin-2. Cells. 2023;12(9):1316. doi:10.3390/cells12091316
   PubMed Web of Science ®Google Scholar
• Cencini E, Sicuranza A, Fabbri A, et al. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. Br J Haematol. 2019;184(2):223–231. doi:10.1111/bjh.15582
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi:10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3067. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Hsu A, Kurt H, Zayac AS, et al. CD5 expression in ­marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab. Leuk Lymphoma. 2022;63(1):31–42. doi:10.1080/10428194.2021.1973670
   PubMed Web of Science ®Google Scholar
• Rai S, Inoue H, Hanamoto H, et al. Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. Int J Hematol. 2021;114(2):205–216. doi:10.1007/s12185-021-03148-0
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175–1183. doi:10.1172/JCI31537
   PubMed Web of Science ®Google Scholar
• Jeyakumar N, Aldoss I, Yang D, et al. Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. Eur J Haematol. 2021;106(6):851–858. doi:10.1111/ejh.13622
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Maurer MJ, Fredericksen ZS, et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol. 2012;87(9):880–885. doi:10.1002/ajh.23273
   PubMed Web of Science ®Google Scholar
• Wróbel T, Mazur G, Dzietczenia J, et al. VEGF and bFGF gene polymorphisms in patients with non-Hodgkin’s lymphoma. Biomed Res Int. 2013;2013:159813. doi:10.1155/2013/159813
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Gurion R, Raanani P, et al. Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol. 2017;35(4):424–431. doi:10.1002/hon.2350
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018;93(1):E1–E3. doi:10.1002/ajh.24921
   PubMed Web of Science ®Google Scholar
• Luminari S, Merli M, Rattotti S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134(10):798–801. doi:10.1182/blood.2019001088
   PubMed Web of Science ®Google Scholar
• Börschel N, Schwöppe C, Zerbst C, et al. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. Leuk Res. 2015;39(7):739–748. doi:10.1016/j.leukres.2015.04.005
   PubMed Web of Science ®Google Scholar
• Fichna M, Zurawek M, Fichna P, et al. Polymorphic variant at the IL2 region is associated with type 1 diabetes and may affect serum levels of interleukin-2. Mol Biol Rep. 2013;40(12):6957–6963. doi:10.1007/s11033-013-2815-9
   PubMed Web of Science ®Google Scholar
• Christensen U, Haagerup A, Binderup HG, et al. Family based association analysis of the IL2 and IL15 genes in allergic disorders. Eur J Hum Genet. 2006;14(2):227–235. doi:10.1038/sj.ejhg.5201541
   PubMed Web of Science ®Google Scholar
• Song H, Chen L, Cha Z, et al. Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. DNA Cell Biol. 2012;31(7):1279–1284. doi:10.1089/dna.2011.1603
   PubMed Web of Science ®Google Scholar
• Matesanz F, Fedetz M, Leyva L, et al. Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol. 2004;148(1-2):212–217. doi:10.1016/j.jneuroim.2003.12.001
   PubMed Web of Science ®Google Scholar
• Wrangle JM, Patterson A, Johnson CB, et al. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 2018;38(2):45–68. doi:10.1089/jir.2017.0101
   PubMed Web of Science ®Google Scholar
• Zhou Y, Quan G, Liu Y, et al. The application of interleukin-2 family cytokines in tumor immunotherapy research. Front Immunol. 2023;14:1090311. doi:10.3389/fimmu.2023.1090311
   PubMed Web of Science ®Google Scholar
• Mortara L, Balza E, Bruno A, et al. Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol. 2018;9:2905. doi:10.3389/fimmu.2018.02905
   PubMed Web of Science ®Google Scholar